SCHEMBL5843828

SCHEMBL5843828

O=C(Nc1ccc(Nc2ccccc2)cc1)C1CC(=O)N(CCc2ccccn2)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
GLA P06280 1/20 0.50
RAB9A P51151 1/20 0.50
PKM P14618 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 2/20 0.46
GAA P10253 1/20 0.46
GFER P55789 1/20 0.46
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842238 0.87 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5843962 0.85 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL6613455 0.83 NPC1 (0.45) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5841926 0.82 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5844160 0.82 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2KMT2AHPGDHTT
SCHEMBL5841681 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5841684 0.81 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5841935 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5842543 0.80 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2KMT2ALMNANPC1
SCHEMBL5842182 0.79 NPSR1 (0.48) ALDH1A1SMN1; SMN2KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 US disclosed
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed
US-20040198780-A1 Inhibitors of cathepsin S IRM LLC (BM) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R ALDH1A1 3034/4885SMN1; SMN2 3678/4885KMT2A 3347/4885
US-20040198780-A1 Inhibitors of cathepsin S CTSS, CTSK, CTSE ALDH1A1 4380/4885SMN1; SMN2 3203/4885KMT2A 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.